NCT00133887

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors.

Conditions

• Skin Cancer
• Kidney Transplantation

Interventions

Type	Name	Description
DRUG	rapamycin	3 to 5 mg/day
DRUG	ciclosporine	Blood residual level \< or = to 125 ng/ml
DRUG	tacrolimus	Blood residual level \< or = to 8 ng/ml

Timeline

• Start date: 2004-04-01
• Primary completion: 2011-03-01
• Completion: 2014-05-01
• First posted: 2005-08-24
• Last updated: 2025-12-26

Locations

1 site across 1 country: France